DigitalCommons@SHU

The Time Course of Development and Impact From Viral Resistance Against Ganciclovir in Cytomegalovirus Infection, C. da Cunha‐Bang, C. da Cunha‐Bang, N. Kirkby, M. Sønderholm, S. S. Sørensen, H. Sengeløv, M. Iversen, A. Rasmussen, F. Gustafsson, C. M. Frederiksen, J. Kjær, A. Cozzi Lepri, J. D. Lundgren, J. D. Lundgren
Maura Iversen

Regarding: Humar et al. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients. Am J Transplant 2010;10:1228–1237, C. da Cunha-Bang, M. Iversen, S. A. Mortensen, A. Rasmussen, H. Sengeløv, S. S. Sørensen, J. Lundgren
Maura Iversen

Regarding: Humar et al. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients, C. Da Cunha-Bang, M. Iversen, S. A. Mortensen, A. Rasmussen, H. Sengeløv, S. S. Sørensen, J. Lundgren
Maura Iversen